de Bruin Gijsbert J, Bac Dirk J, van Puijenbroek Eugène P, van der Klooster Johan M
Sint Franciscus Gasthuis, afd. Intensive Care, Rotterdam, The Netherlands.
Ned Tijdschr Geneeskd. 2009;153:B437.
Clozapine is an antipsychotic drug which is used in the treatment of therapy-resistant schizophrenia. The most frequently reported side effects (occurring in more than 10% of patients) are gastro-intestinal complaints, including constipation. Here we describe the case of a 28-year-old man with schizophrenia who developed constipation and abdominal distension for several weeks while taking clozapine. He was admitted as an emergency suffering from clozapine-induced Ogilvie syndrome (acute pseudo-obstruction caused by a disturbed balance in the autonomic regulation of intestinal motility). Treatment on the intensive care unit was required because of septic shock and multiple organ dysfunction syndrome. Colonoscopy showed severe ischaemic colitis without signs of perforation or obstruction. Because conservative treatment with enemas, prokinetic drugs and antibiotics did not have sufficient effect, the cholinergic drug neostigmine was added to the treatment regimen. This led to a good clinical response, thereby averting the need for surgery. This case illustrates that decreased intestinal motility can be a severe problem for patients taking clozapine, which may lead to life-threatening complications.
氯氮平是一种用于治疗难治性精神分裂症的抗精神病药物。最常报告的副作用(发生率超过10%的患者)是胃肠道不适,包括便秘。在此,我们描述一例28岁精神分裂症男性患者的病例,该患者在服用氯氮平期间出现了数周的便秘和腹胀。他因氯氮平诱发的奥吉尔维综合征(由肠道运动自主调节平衡紊乱引起的急性假性肠梗阻)而急诊入院。由于感染性休克和多器官功能障碍综合征,需要在重症监护病房进行治疗。结肠镜检查显示严重缺血性结肠炎,无穿孔或梗阻迹象。由于灌肠、促动力药物和抗生素的保守治疗效果不佳,治疗方案中添加了胆碱能药物新斯的明。这带来了良好的临床反应,从而避免了手术的需要。该病例表明,肠道蠕动减慢对服用氯氮平的患者可能是一个严重问题,可能导致危及生命的并发症。